Overview

Prucalopride Versus Placebo in Gastroparesis

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Controlled cross-over study of prucalopride 2 mg daily or placebo in gastroparesis (idiopathic or diabetic). Patients will be randomized to 4 week treatment with the first regimen (double-blind), followed by a 2-week washout and 4 week treatment with the second regimen in cross-over.
Phase:
Phase 4
Details
Lead Sponsor:
Universitaire Ziekenhuizen Leuven
Treatments:
Prucalopride